Squamous Cell Carcinoma Clinical Pipeline | 75+ Companies Advancing the Future of Treatment

The Squamous Cell Carcinoma market is rapidly evolving with cutting-edge research and breakthrough therapies driven by leading companies like AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, and MacroGenics. These innovators are revolutionizing treatment approaches and shaping the future of Squamous Cell Carcinoma care, offering new hope for patients worldwide.

DelveInsight's 'Squamous Cell Carcinoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Squamous Cell Carcinoma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Squamous Cell Carcinoma pipeline domain.

For emerging Squamous Cell Carcinoma drugs, the Squamous Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Squamous Cell Carcinoma Pipeline Report
• DelveInsight's Squamous Cell Carcinoma Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline drugs for Squamous Cell Carcinoma treatment.
• The leading Squamous Cell Carcinoma companies include Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others are evaluating their lead assets to improve the Squamous Cell Carcinoma treatment landscape.
• Key Squamous Cell Carcinoma pipeline therapies in various stages of development include Cosibelimab (CK-301), INCB99280, NBTXR-3, mRNA-4157, HB-200, MCLA-158, HFB-301001, and others.
• In Feb 2025, the FDA granted fast-track designation to Pyxis Oncology's antibody-drug conjugate (ADC), PYX-201, for treating adults with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
• In December 2024, Checkpoint Therapeutics, Inc. announced that the FDA approved UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.

Request a sample and discover the recent breakthroughs happening in the Squamous Cell Carcinoma pipeline landscape @ https://www.delveinsight.com/report-store/squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Squamous Cell Carcinoma Overview
Squamous cell carcinoma (SCC) is a malignancy arising from squamous cells in the epidermis and can develop in various parts of the body, including the skin, lungs, head and neck, esophagus, urinary tract, prostate, vagina, and cervix. It is the second most common skin cancer, accounting for about 20% of cases, and is known for its aggressive nature and potential for metastasis. Chronic exposure to ultraviolet (UV) radiation, especially in early life, is the primary risk factor for cutaneous SCC, while other contributing factors include immunosuppression, chronic inflammation, and genetic mutations such as those in the p53 gene. SCC often presents as rough, scaly patches, open sores, wart-like growths, or firm nodules, sometimes appearing in sun-protected areas. Depending on its location, SCC may also cause pain, itching, or numbness.

Treatment varies based on the site and stage of SCC, requiring a multidisciplinary approach. In lung SCC, surgery is typically followed by chemotherapy, with lobectomy preferred for stage II tumors, while sub-lobar resection may be considered when surgery is not viable. Head and neck SCC treatment options include surgery, radiation, chemotherapy, and targeted therapies, either alone or in combination, with an emphasis on preserving function and quality of life. Advances in diagnostic techniques and treatment strategies continue to improve survival rates, but close monitoring and follow-up remain crucial for managing the disease and addressing potential complications.

Find out more about Squamous Cell Carcinoma medication @ https://www.delveinsight.com/report-store/squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Squamous Cell Carcinoma Treatment Analysis: Drug Profile
NBTXR-3: Nanobiotix
NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with squamous cell carcinoma.

mRNA-4157: Moderna Therapeutics
mRNA-4157 is an investigational personalized mRNA cancer vaccine, Merck's anti-PD-1 therapy, for the adjuvant treatment of patients with squamous cell carcinoma. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with squamous cell carcinoma.

HB-200: Hookipa Pharma
HB-200 is HOOKIPA's lead oncology candidate engineered with the company's proprietary replicating arenaviral vector platform. HB-200 is an alternating 2-vector immunotherapy designed to focus the immune response against the encoded antigen. It comprises two single-vector compounds with arenaviral backbones based on LCMV and PICV. Both encode and express an identical E7E6 fusion protein, comprising well characterized tumor-specific antigens for HPV16+ cancers. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with squamous cell carcinoma.

MCLA-158: Merus
MCLA-158 (also known as Petosemtamab) is a Biclonics low-fucose human full-length IgG1 antibody targeting the epidermal growth factor receptor (EGFR) and the leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5). The drug is designed to exhibit three independent mechanisms of action including inhibition of EGFR-dependent signaling, LGR5 binding leading to EGFR internalization and degradation in cancer cells, and enhanced antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis activity. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with squamous cell carcinoma.

Key Squamous Cell Carcinoma Therapies and Companies
• Cosibelimab (CK-301): Checkpoint Therapeutics
• INCB99280: Incyte Corporation
• NBTXR-3: Nanobiotix
• mRNA-4157: Moderna Therapeutics
• HB-200: Hookipa Pharma
• MCLA-158: Merus
• HFB-301001: HiFiBiO

Learn more about the novel and emerging Squamous Cell Carcinoma pipeline therapies @ https://www.delveinsight.com/report-store/squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Squamous Cell Carcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

By Molecule Type
• Monoclonal antibody
• Small molecule
• Peptide

Scope of the Squamous Cell Carcinoma Pipeline Report
• Coverage: Global
• Key Squamous Cell Carcinoma Companies: Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Merus, and others.
• Key Squamous Cell Carcinoma Pipeline Therapies: Cosibelimab (CK-301), INCB99280, NBTXR-3, mRNA-4157, HB-200, MCLA-158, HFB-301001, and others.

Dive deep into rich insights for drugs used for Squamous Cell Carcinoma treatment; visit @ https://www.delveinsight.com/report-store/squamous-cell-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Squamous Cell Carcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Squamous Cell Carcinoma Pipeline Therapeutics
6. Squamous Cell Carcinoma Pipeline: Late-Stage Products (Phase III)
7. Squamous Cell Carcinoma Pipeline: Late-Stage Products (Phase III)
8. Squamous Cell Carcinoma Pipeline: Mid-Stage Products (Phase II)
9. Squamous Cell Carcinoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.